Skip to content
Peptide research

Syn-Ake

Also known as Dipeptide Diaminobutyroyl Benzylamide Diacetate
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A synthetic tripeptide mimicking waglerin-1 from Temple Viper venom, used topically to relax facial muscles and soften expression lines as a Botox alternative. Evidence remains limited, with laboratory findings and small industry-affiliated human studies. The main risk is poor skin penetration that may keep it from reaching muscle, plus inconsistent quality. It is a cosmetic ingredient, not an approved drug, sold in skincare products and as unregulated products online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Syn-Ake is a synthetic tripeptide designed to mimic the muscle-relaxing effect of a component found in temple viper venom — but without using any actual venom. Developed by the Swiss company Pentapharm (now DSM-Firmenich) in 2004, it works by temporarily relaxing the tiny facial muscles that cause expression lines like crow's feet and forehead wrinkles. Often called a 'topical Botox alternative,' Syn-Ake is one of the most widely used anti-aging peptides in skincare, found in hundreds of products worldwide and protected by over 160 patents.

How it works in the body

A tripeptide that mimics waglerin-1, a peptide from the Temple Viper's venom. It acts as a reversible antagonist at the muscular nicotinic acetylcholine receptor (nAChR), reducing muscle cell contraction. Applied topically, it relaxes facial muscle tension to smooth expression lines.

Research overview

Syn-Ake works by blocking the signal between nerves and facial muscles at the skin's surface — the same general principle as Botox, but applied topically and much more gently. In lab tests, it reduced muscle contractions by up to 82%. In the manufacturer's 28-day study, volunteers applied a cream containing 4% of the ingredient twice daily; wrinkle depth fell by up to 52%, and 80% of volunteers showed visible smoothing. A 2025 review found Syn-Ake present in 81% of viper-venom-themed skincare products on the market. However, the main human data come from the manufacturer rather than independent peer-reviewed trials, and no studies on ClinicalTrials.gov exist for this ingredient.

Who researches Syn-Ake?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching reduction of expression wrinkles and crow's feet

    One of the primary studied benefits of Syn-Ake.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Limited independent clinical validation

    High

    PMID 37349941; PMID 41668671

  • Poor skin penetration may limit efficacy

    Moderate

    Mechanistic/formulation reasoning; no penetration study indexed in PubMed

  • Product quality variability

    Moderate

    Regulatory status (cosmetic, not FDA drug); no OTC monograph

  • Skin irritation and allergic reaction

    Low

    PMID 37349941

  • Pregnancy and lactation safety unknown

    Low

    No published reproductive toxicology data

  • Acute dermal toxicity at high concentrations

    Theoretical

    PMID 7638875; PMID 37349941

Interaction summary(7)

Rated by direction with this peptide

  • Myasthenia gravis, Lambert-Eaton syndrome, ALS and other neuromuscular junction disorders

    CautionTheoretical

    Syn-Ake's target is the same muscle nicotinic receptor that is already compromised in these conditions, so any meaningful systemic absorption would be pharmacologically unwelcome — though no case of clinical worsening from topical use has been reported.

    Mechanism: PMID 10087048; PMID 12069578

  • Acetylcholinesterase inhibitors (pyridostigmine, neostigmine, donepezil, rivastigmine)

    CautionTheoretical

    Direct pharmacologic antagonism — these drugs work by raising acetylcholine at the nicotinic receptor that Syn-Ake reversibly blocks — but expected systemic exposure from a facial serum makes clinically relevant opposition very unlikely.

    Mechanism: PMID 10087048

  • Botulinum toxin type A (onabotulinumtoxinA and related neuromodulators)

    SynergisticTheoretical

    Both reduce mimetic muscle contraction but at different points (presynaptic ACh release vs. postsynaptic receptor block); no clinical study has tested the combination.

    Mechanistic; no combination trial indexed in PubMed

  • Acetyl hexapeptide-8 (Argireline) and other SNAP-25/neuropeptide cosmetic actives

    SynergisticLow

    The 2026 clinical serum data formulates acetyl hexapeptide-8 with dipeptide diaminobutyroyl benzylamide diacetate — but the trial cannot separate their individual contributions.

    PMID 41668671

  • Topical retinoids, alpha/beta hydroxy acids and other barrier-disrupting actives

    CautionLow

    These increase stratum corneum permeability, which may raise both peptide delivery and the likelihood of stinging or irritation when layered in the same routine.

    General dermatologic formulation principle

  • Microneedling, ablative laser resurfacing, or application to broken/compromised skin

    CautionTheoretical

    Bypassing the stratum corneum removes the main barrier limiting systemic delivery of a neuromuscular-active peptide, so post-procedure application is best avoided until the barrier is intact.

    Mechanistic; no safety study of post-procedure use

  • Aminoglycoside antibiotics and magnesium sulfate (agents that impair neuromuscular transmission)

    CautionTheoretical

    Additive neuromuscular blockade is conceivable in principle, but no absorption data suggest a topical tripeptide reaches plasma levels where this would matter — listed for completeness, not as an observed interaction.

    Mechanistic only; no reports

Known risks(6)

  • Skin irritation and allergic reaction

    Low

    Some individuals, particularly those with sensitive skin, have reported mild reactions including redness, itching, stinging, or localized swelling upon application of Syn-Ake products. These reactions are generally transient and resolve upon discontinuation. Allergic contact dermatitis is possible but rare. A patch test is recommended before first use.

  • Acute dermal toxicity at high concentrations

    Low (in cosmetic use) / Moderate (raw material handling)

    Safety data sheets classify pure dipeptide diaminobutyroyl benzylamide diacetate as 'Acute toxicity - Category 3, Dermal' with the hazard statement 'Toxic in contact with skin.' However, this classification applies to the concentrated raw material, not to the dilute concentrations used in finished cosmetic products (typically 0.01-5%). At recommended cosmetic concentrations, the ingredient is not associated with significant toxicity. Formulators and handlers of the raw material should use appropriate PPE.

  • Limited independent clinical validation

    Moderate (uncertainty)

    The primary efficacy claims for Syn-Ake derive from manufacturer-sponsored studies that have not been independently replicated in peer-reviewed, double-blind, randomized controlled trials. The 2024 review by Nguyen et al. noted only six total clinical validations for all Botox-like peptides combined. Consumers should have realistic expectations and understand that the claimed 52% wrinkle reduction has not been verified by independent research groups.

  • Poor skin penetration may limit efficacy

    Moderate (efficacy concern)

    Peptide penetration through the stratum corneum (the skin's outer barrier) is a well-documented challenge in cosmeceutical science. The 2025 Biomolecules review (PMID 39858482) identified poor membrane permeability as one of the most significant drawbacks of cosmetic peptides. In vitro results showing 82% reduction in muscle contractions may not translate to equivalent in vivo effects due to limited bioavailability at the target muscle layer. Delivery systems (liposomes, penetration enhancers, microneedling) may improve efficacy but are not standard in most products.

  • Pregnancy and lactation safety unknown

    Low-Moderate (precautionary)

    No reproductive or developmental toxicity studies have been conducted with Syn-Ake. While the topical cosmetic use at low concentrations is unlikely to pose systemic risk, there is no data confirming safety during pregnancy or breastfeeding. Consult a healthcare provider if pregnant or nursing.

  • Product quality variability

    Low-Moderate

    The 2025 Applied Sciences market analysis found Syn-Ake concentrations in commercial products ranging from 0.01% to 4% — a 400-fold range. Many products contain trace amounts insufficient for clinical effect but use Syn-Ake as a marketing label claim. Generic versions from various manufacturers may have different purity profiles than the original DSM-Firmenich SYN-AKE. Consumers should look for products disclosing concentration.

Drug interactions(5)

  • AHA/BHA chemical exfoliants (glycolic acid, salicylic acid, lactic acid)

    Strong acids can degrade peptide bonds, reducing Syn-Ake's effectiveness when applied simultaneously. Glycolic acid (AHA) and salicylic acid (BHA) create a low-pH environment that may hydrolyze the peptide before it reaches target receptors. Recommended approach is to use acid exfoliants and Syn-Ake products at different times of day or on alternating nights to avoid direct interaction.

  • Retinoids (retinol, tretinoin, adapalene)

    Compatible combination. Syn-Ake and retinoids target different aspects of skin aging — Syn-Ake addresses dynamic wrinkles through muscle relaxation while retinoids promote cell turnover and collagen production for static wrinkles. No pharmacological overlap or interference has been documented. The combination addresses both dynamic and static wrinkle formation simultaneously and is considered beneficial by dermatologists.

  • Other neuromuscular-inhibiting peptides (Argireline/Acetyl Hexapeptide-8, SNAP-8)

    Theoretically additive effects. Syn-Ake acts postsynaptically (blocking nAChR) while Argireline and SNAP-8 act presynaptically (inhibiting SNARE complex and acetylcholine release). Combining pre- and post-synaptic neuromuscular inhibitors targets the neuromuscular junction from both sides. Several commercial products combine these peptides. No adverse interactions have been reported, but independent clinical data on combined efficacy is lacking.

  • Botulinum toxin (Botox, Dysport, Xeomin)

    Potentially additive neuromuscular effects. Both Botox and Syn-Ake reduce facial muscle activity through different mechanisms. Topical Syn-Ake is commonly used as a maintenance treatment between Botox injection sessions. The extremely limited systemic absorption of topical Syn-Ake makes clinically significant additive effects unlikely, but no formal interaction studies exist. Patients should inform their dermatologist if using neuromuscular-targeting topicals.

  • Copper peptides (GHK-Cu)

    Compatible combination. Copper peptides stimulate collagen synthesis and wound healing through mechanisms unrelated to Syn-Ake's neuromuscular action. However, copper ions can potentially catalyze oxidation of peptide bonds. Using copper peptide products and Syn-Ake products in separate application steps (not mixed directly) is advisable.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
12
Human Studies
2

The clinical evidence base for Syn-Ake is limited to manufacturer-sponsored efficacy data and supportive mechanistic research. The primary efficacy claim — up to 52% wrinkle reduction after 28 days — comes from Pentapharm's in-house in vivo study using 4% Syn-Ake cream, which measured skin surface parameters objectively (profilometry) but was not published in a peer-reviewed journal or independently replicated. The underlying mechanism (nAChR antagonism causing muscle relaxation) is well-supported by independent academic research on waglerin-1 peptides (Molles et al. 1999, McArdle et al. 2002). A 2024 study (Bang et al., PMID 39063099) independently confirmed Syn-Ake's nAChR inhibitory activity but primarily as a comparison control for a novel peptide. The 2024 review by Nguyen et al. in Cosmetics noted only six clinical validations total for Botox-like peptides (including Syn-Ake, Argireline, and SNAP-8). Major evidence gaps include: (1) no independent RCTs, (2) no long-term efficacy or safety data, (3) no head-to-head comparison with Botox or other neuromuscular peptides in peer-reviewed trials, and (4) the well-documented challenge of poor peptide permeability through the stratum corneum, which may limit in vivo efficacy compared to in vitro results.

Researched for(5)

Rated by confidence in the evidence

  • Reduction of expression wrinkles and crow's feet

    Speculative

    A 2026 controlled split-face pilot included five Syn-Ake participants; larger replication is needed.

    PMID 41668671

  • Non-invasive muscle relaxation (topical Botox alternative)

    Speculative

    Receptor inhibition has laboratory support. Human topical studies exist, but do not directly establish facial-muscle relaxation.

    PMID 10087048; PMID 7638875; PMID 12069578

  • Antioxidant activity and ROS scavenging

    Speculative

    Based on a single in vitro chemical assay, not cellular or human testing.

    PMID 37349941

  • Skin smoothing and texture improvement

    Speculative

    Reported only in a multi-ingredient serum trial; not isolated to Syn-Ake.

    PMID 41668671

  • Potential collagen and elastin stimulation

    Speculative

    Computational binding studies only; matrix effects seen were from the full formula.

    PMID 37349941; PMID 41668671

Benefits(5)

  • Reduction of expression wrinkles and crow's feet

    Pentapharm in vivo study (2005-2006) — 28-day trial in volunteers applying a cream containing 4% of the commercial Syn-Ake ingredient to the forehead twice daily. Measurements of surface roughness (Ra), wrinkle depth (Rz), and total wrinkle height (Rt) showed up to 52% reduction in wrinkle depth, with 80% of volunteers showing measurable smoothing and 73% showing wrinkle reduction. Bang et al. 2024 (Int J Mol Sci, PMID 39063099) — Comparative study confirmed Syn-Ake's inhibition of nicotine responses at nmAChR, with responses of 98%, 52.5%, and 3.5% at concentrations of 100, 250, and 500 micromolar respectively.

  • Non-invasive muscle relaxation (topical Botox alternative)

    Nguyen et al. 2024 (Cosmetics, doi: 10.3390/cosmetics11040118) — Review of non-invasive peptides as Botox alternatives noted that Syn-Ake replicates the neuromodulatory effects of botulinum toxin through nAChR antagonism, achieving up to 52% wrinkle reduction within 4 weeks without injections. Pentapharm in vitro data demonstrated Syn-Ake reduces acetylcholine-induced muscle cell contractions by up to 82% through reversible blocking of the ion channel at the nmAChR epsilon subunit.

  • Antioxidant activity and ROS scavenging

    In vitro DPPH free radical scavenging assays demonstrated that dipeptide diaminobutyroyl benzylamide diacetate exhibits noticeable antioxidant activity in a dose-dependent manner. Molecular docking studies revealed strong binding affinity to aging-related proteins, suggesting that Syn-Ake may help protect skin cells from oxidative stress beyond its primary neuromuscular mechanism. Referenced in Moisă et al. 2025 (Appl Sci, doi: 10.3390/app15084501) review of viper venom peptides in cosmeceuticals.

  • Skin smoothing and texture improvement

    Pentapharm in vivo study (2005-2006) — After 28 days of twice-daily application of 4% Syn-Ake cream, skin smoothness improved by approximately 21%, with maximum improvements in skin texture observed in the majority of the volunteer cohort. Improvements were reported as early as 7 days, with enhanced skin texture and decreased wrinkle size in facial areas prone to expression lines.

  • Potential collagen and elastin stimulation

    Emerging evidence suggests Syn-Ake may stimulate production of collagen and elastin, the primary structural proteins in the skin, beyond its neuromuscular mechanism. In vitro studies on related nAChR-targeting peptides (Bang et al. 2024, PMID 39063099) showed increased collagen synthesis in skin cells and upregulation of aquaporin-3 (AQP3) and hyaluronan synthase-2 (HAS2) gene expression. Whether these effects extend specifically to Syn-Ake remains under investigation.

Key studies(5)

  1. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor

    In vitro receptor binding studyMouse neuromuscular preparations, including epsilon-subunit knockout mice.N/A (mechanistic study)

    McArdle JJ, Lentz TL, Witzemann V, Schwarz H, Weinstein SA, Schmidt JJ

    Journal of Pharmacology and Experimental Therapeutics

    1999

    Waglerin-1, the parent molecule for Syn-Ake, selectively inhibited epsilon-containing mouse muscle nAChRs; topical Syn-Ake efficacy and cross-species affinity ratios were not tested.

  2. Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream

    Evolutionary biology / molecular analysisComparative venom transcriptomics of Tropidolaemus and Azemiops speciesN/A (evolutionary study)

    Debono J, Xie B, Violette A, Fourmy R, Jaeger M, Fry BG

    Journal of Molecular Evolution

    2017

    Traced the molecular origin and evolution of waglerin peptides used in anti-wrinkle skin cream (Syn-Ake). Demonstrated that waglerins arose from de novo evolution within the prepro region of the C-type natriuretic peptide gene in Tropidolaemus venoms, at a site distinct from the domain encoding natriuretic peptide. Related azemiopsin peptides from Azemiops feae share the same gene origin, indicating a close evolutionary relationship. This study provided the first comprehensive molecular evolutionary context for the venom peptides that inspired the Syn-Ake cosmeceutical.

  3. Wrinkle-Improving Effect of Novel Peptide That Binds to Nicotinic Acetylcholine Receptor

    In vitro and in vivo comparative studyCell cultures and human volunteer skin assessment6 weeks topical application of Medipep

    Bang J, Hwang YL, Kim MY, Yun JN, Hyun E, Chang MY, Shin DH, Kim S, Lee JH

    International Journal of Molecular Sciences

    2024

    Compared Syn-Ake (SYN-AKE) to a novel nAChR-targeting peptide (Medipep/Palmitoyl Hexapeptide-93). Independently confirmed Syn-Ake's nAChR inhibitory activity: nicotine responses of 98%, 52.5%, and 3.5% at concentrations of 100, 250, and 500 micromolar. The novel peptide achieved similar inhibition at approximately 1/100th the concentration, suggesting Syn-Ake has moderate potency. Medipep increased collagen synthesis and AQP3 and HAS2 expression. Syn-Ake served as a receptor-inhibition comparator; these matrix-related findings were not established for Syn-Ake.

  4. Sustainable Dynamic Wrinkle Efficacy: Non-Invasive Peptides as the Future of Botox Alternatives

    Systematic reviewReview of clinical validations across multiple peptidesN/A (review article)

    Nguyen TTM, Yi EJ, Jin X, Zheng Q, Park SJ, Yi GS, Yang SJ, Yi TH

    Cosmetics

    2024

    Comprehensive review examining non-invasive peptides as Botox alternatives. Highlighted Syn-Ake and Argireline as noteworthy peptides that replicate neuromodulatory effects of Botox, achieving up to 52% wrinkle reduction within 4 weeks without injections. Noted that only six total clinical validations exist for Botox-like peptide anti-wrinkle efficacy. Identified low skin absorption rate as the main challenge for peptide effectiveness compared to injectable Botox (which achieves up to 80% wrinkle reduction within one week).

  5. Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals

    Market analysis and systematic reviewAnalysis of 245 commercial cosmetic productsN/A (review and market survey)

    Moisă DG, Juncan AM, Rus LL, Vonica-Țincu AL, Cormoș G, Gligor FG

    Applied Sciences (MDPI)

    2025

    Analyzed 245 products. Ingredient lists identified Syn-Ake in 199 products (about 81%) and snake or viper venom in 31 products (about 13%); claimed Syn-Ake concentrations ranged from 0.01% to 4%. Concluded that the cosmeceuticals market overwhelmingly favors the synthetic analog over natural venom, reflecting Syn-Ake's commercial dominance. Noted critical challenges remain regarding efficacy validation, safety studies, and regulatory compliance.

Regulation & availability

Why researchers look at it

The manufacturer's 28-day study reported up to 52% reduction in wrinkle depth, and the ingredient now appears in 81% of viper-venom-themed skincare products — but no independent peer-reviewed clinical trial has ever been published. Whether enough peptide actually penetrates skin to reach facial muscles remains an open question. Independent validation could establish it as a legitimate topical alternative to Botox.

Estimated cost
$20-60/mo in OTC serums
FDA status
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is marketed as a topical cosmetic ingredient. No FDA-approved drug product or indication was identified. Cosmetic products generally do not require FDA premarket approval, but manufacturers remain responsible for safety substantiation and compliance; a product that claims to treat a condition or change how the body works is regulated as a drug. Syn-Ake was not found in the reviewed FDA 503A or 503B category lists. In the EU, CosIng provides ingredient information; inclusion does not constitute approval, and finished products require a safety assessment and compliance with Regulation (EC) No 1223/2009. No regulatory body imposes a specific concentration limit, though the manufacturer recommends 1-5% for efficacy. The Environmental Working Group (EWG) Skin Deep database rates it 1 out of 10 (lowest hazard), the EPA CompTox Chemicals Dashboard lists it under DTXSID40231699, and no adverse event reports related to Syn-Ake have been documented in major regulatory databases.
WADA status
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is NOT on the WADA Prohibited List and is not prohibited in any category of sport. The 2026 WADA Prohibited List restricts certain peptide hormones, growth factors, and related substances under class S2, including GH-releasing peptides (GHRPs), thymosin-beta-4 derivatives, and growth factor modulators. Syn-Ake does not fall into any of these categories — it is a cosmeceutical neuromuscular-inhibiting tripeptide with no hormonal, anabolic, or performance-enhancing activity. Furthermore, Syn-Ake is a topical-only cosmetic ingredient with negligible systemic absorption, making it irrelevant to anti-doping considerations. Athletes may use Syn-Ake-containing skincare products without any WADA compliance concerns.
Prescribability
Syn-Ake is NOT a prescription drug and is NOT FDA-approved as a pharmaceutical. It is classified as a cosmetic ingredient, not a drug, and therefore does not require a prescription. Syn-Ake is widely available as an over-the-counter (OTC) cosmetic ingredient in serums, creams, eye treatments, and other topical skincare products globally. The original SYN-AKE is a trademarked active ingredient manufactured by DSM-Firmenich (formerly Pentapharm Ltd), which supplies it to cosmetic formulators and brands worldwide. Generic versions of dipeptide diaminobutyroyl benzylamide diacetate are also produced by multiple peptide synthesis companies. It is not available through compounding pharmacies as a pharmaceutical preparation, as it is intended solely for topical cosmetic use.
Availability
Syn-Ake is widely available because it is a cosmetic ingredient rather than a regulated pharmaceutical. It is incorporated into hundreds of commercially available anti-aging serums, creams, eye treatments, masks, and other skincare products from brands worldwide, ranging from budget formulations to premium skincare lines. Concentrations typically range from 0.01% to 5%, with a manufacturer-recommended optimal concentration of 4%. The original SYN-AKE is a trademarked ingredient from DSM-Firmenich for cosmetic manufacturers and formulators; generic dipeptide diaminobutyroyl benzylamide diacetate is also made by other peptide synthesis companies for cosmetic formulation. No prescription is required in any jurisdiction, as Syn-Ake is regulated as a cosmetic ingredient globally.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(11)

  1. 1992
    Schmidt et al. publish first characterization of molecular properties of lethal peptides (waglerins) from Wagler's pit viper (Trimeresurus wagleri), establishing the scientific foundation for understanding waglerin peptides.
  2. 1995
    Schmidt & Bhatt publish structure-function studies of waglerin I, identifying residues critical for bioactivity and laying groundwork for synthetic analog development.
  3. 1999
    McArdle et al. demonstrate selective inhibition of epsilon-containing mouse muscle nAChRs by waglerin-1. This foundational finding establishes the molecular target for cosmetic peptide design.
  4. 2004
    Pentapharm Ltd (Switzerland) first synthesizes Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate), a tripeptide mimicking the essential nAChR-blocking sequence of waglerin-1 for safe topical cosmetic use.
  5. 2005-2006
    Pentapharm conducts key in vivo efficacy study: 28-day trial of 4% Syn-Ake cream showing up to 52% wrinkle depth reduction. Results presented in technical dossier and at cosmetics industry conferences.
  6. 2006
    Pentapharm patents Syn-Ake and wins the Swiss Technology Award 2006 for the innovation. Over 160 patents filed across the US, EU, and Asia for cosmetic applications.
  7. 2007
    DSM acquires Pentapharm Ltd, bringing Syn-Ake under the DSM portfolio of cosmetic active ingredients. Syn-Ake begins widespread commercialization in global skincare market.
  8. 2017
    Debono et al. publish in Journal of Molecular Evolution the molecular origin and evolution of waglerin peptides, providing evolutionary context for the peptides used in Syn-Ake formulations (PMID 27864608).
  9. 2023
    DSM completes merger with Firmenich to form DSM-Firmenich. Syn-Ake continues as a key active ingredient in the combined company's Beauty & Care division.
  10. 2024
    Bang et al. publish independent comparative study (PMID 39063099) confirming Syn-Ake's nAChR inhibitory activity; Nguyen et al. review (Cosmetics) places Syn-Ake among leading non-invasive Botox alternative peptides.
  11. 2025
    Moisă et al. market analysis (Applied Sciences) finds Syn-Ake present in about 81% of viper-venom-themed cosmeceutical products, confirming market dominance. Ciccone et al. review (Biomolecules, PMID 39858482) classifies Syn-Ake among neurotransmitter inhibitor peptides for skin senescence prevention.

Sources & FAQs

Research sources(15)

Frequently asked questions(4)

How does Syn-Ake compare to Botox for wrinkle reduction?

Syn-Ake and Botox (botulinum toxin) share a similar goal — reducing expression wrinkles by relaxing facial muscles — but they work through different mechanisms and routes. Botox is an injectable that prevents acetylcholine release from the presynaptic nerve terminal (blocking the SNARE complex), achieving up to 80% wrinkle reduction within one week. Syn-Ake is a topical peptide that blocks the postsynaptic nAChR, preventing acetylcholine from activating the muscle, achieving up to 52% wrinkle reduction after 28 days. The key advantages of Syn-Ake are non-invasiveness (no needles), lower cost, no prescription needed, and daily at-home use. The key disadvantages are lower efficacy, slower onset, the challenge of peptide penetration through the skin barrier, and limited independent clinical validation. Syn-Ake is best viewed as a maintenance option between Botox treatments or as an alternative for people who do not want injections.

Is Syn-Ake safe for sensitive skin?

Syn-Ake is generally considered safe for topical use. The EWG rates it 1/10 (minimal hazard), and no significant adverse effects have been documented in regulatory databases. However, some individuals with sensitive skin have reported mild reactions including redness, itching, stinging, or swelling at the application site. As with any new skincare ingredient, a patch test is recommended before full facial application. Safety data sheets classify the pure compound as 'Acute toxicity - Category 3, Dermal' at concentrated levels, but the dilute concentrations used in cosmetic products (typically 0.01-5%) are well below toxic thresholds. Pregnant or breastfeeding individuals should consult a healthcare provider before use, as no reproductive safety data is available.

What concentration of Syn-Ake should I look for in products?

The manufacturer (DSM-Firmenich / formerly Pentapharm) recommends 4% Syn-Ake for optimal anti-wrinkle results, which is the concentration used in their clinical efficacy studies. Effective concentrations generally range from 1-5%, with different product types using different levels: dedicated serums typically contain 3-5%, eye creams 1-3% (due to the delicate eye area), and night creams 4-5% for intensive overnight treatment. Many commercial products use significantly lower concentrations (as low as 0.01%) to include Syn-Ake on the label at reduced cost. For meaningful results, look for products with at least 2-4% concentration, and be aware that improvements typically become visible within 5-7 days with full effects at 28 days of consistent twice-daily application.

Does Syn-Ake have any longevity or systemic health benefits?

No. Syn-Ake is exclusively a topical cosmetic peptide with effects limited to the skin surface. It has no systemic bioavailability when applied topically and has never been studied for systemic health outcomes, lifespan extension, or longevity biomarkers. Its antioxidant properties (ROS scavenging) are relevant only to local skin cell protection. Unlike peptides such as BPC-157, Thymosin Beta-4, or Epithalon, Syn-Ake has no role in systemic rejuvenation, immune function, or organ-level anti-aging. It is included in longevity peptide databases purely for its role in cosmetic aging — maintaining skin appearance as part of the visible aging phenotype.